1. Home
  2. AMGN vs RTX Comparison

AMGN vs RTX Comparison

Compare AMGN & RTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$437.81

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Logo RTX Corporation

RTX

RTX Corporation

N/A

Current Price

$191.18

Market Cap

269.6B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
AMGN
RTX
Founded
1980
1934
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Aerospace
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
251.6B
269.6B
IPO Year
2002
1994

Fundamental Metrics

Financial Performance
Metric
AMGN
RTX
Price
$437.81
$191.18
Analyst Decision
Hold
Buy
Analyst Count
34
24
Target Price
★ $435.77
$228.13
AVG Volume (30 Days)
2.1M
★ 4.6M
Earning Date
11-03-2026
10-20-2026
Dividend Yield
★ 2.30%
1.51%
EPS Growth
★ 88.23
39.72
EPS
★ 14.79
4.96
Revenue
$25,424,000,000.00
★ $80,738,000,000.00
Revenue This Year
$7.45
$9.93
Revenue Next Year
$4.54
$7.83
P/E Ratio
★ $29.67
$39.00
Revenue Growth
8.83
★ 17.15
52 Week Low
$312.39
$166.74
52 Week High
$483.99
$226.88

Technical Indicators

Market Signals
Indicator
AMGN
RTX
Relative Strength Index (RSI) 41.75 43.44
Support Level $338.02 $190.74
Resistance Level $446.42 $205.18
Average True Range (ATR) 11.75 5.48
MACD -4.96 -0.78
Stochastic Oscillator 4.16 17.03

Price Performance

Historical Comparison
AMGN
RTX

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

Share on Social Networks: